fosamprenavir has been researched along with rivastigmine in 1 studies
| Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (rivastigmine) | Trials (rivastigmine) | Recent Studies (post-2010) (rivastigmine) |
|---|---|---|---|---|---|
| 174 | 55 | 37 | 1,397 | 266 | 633 |
| Protein | Taxonomy | fosamprenavir (IC50) | rivastigmine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 6.2943 | |
| Cholinesterase | Homo sapiens (human) | 1.1886 | |
| Acyl-CoA desaturase 1 | Rattus norvegicus (Norway rat) | 1.71 | |
| Acetylcholine receptor subunit epsilon | Rattus norvegicus (Norway rat) | 9 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.875 | |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 0.875 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 3.9833 | |
| Acetylcholinesterase | Homo sapiens (human) | 2.8567 | |
| Acetylcholinesterase | Bos taurus (cattle) | 0.62 | |
| Cholinesterase | Canis lupus familiaris (dog) | 6.27 | |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | 3.5012 | |
| Tyrosine-protein kinase SYK | Homo sapiens (human) | 0.16 | |
| Beta-secretase 1 | Homo sapiens (human) | 7.72 | |
| Cholinesterase | Equus caballus (horse) | 2.1636 | |
| Cholinesterase | Mus musculus (house mouse) | 0.829 | |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | 5.2767 | |
| Carboxylic ester hydrolase | Equus caballus (horse) | 0.495 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fosamprenavir and rivastigmine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |